The sustained efficacy and safety of eszopiclone over six months
Common Questions and Answers about The sustained efficacy and safety of eszopiclone over six months
lunesta
COSMOS - Study Design
COSMOS is a phase IIa, randomized, open-label study investigating the safety and efficacy of simeprevir in combination with sofosbuvir, with and without ribavirin, for either 12 or 24 weeks. The study enrolled HCV genotype 1 patients who were prior null responders to treatment with interferon and ribavirin with METAVIR F0-F2 scores (cohort 1, n=80), or treatment-naïve patients and prior null responders with METAVIR F3-F4 scores (cohort 2, n=87).
The focus of this study was to evaluate the safety and efficacy of sequential peginterferon α-2a (Pegasys) therapy for chronic hepatitis B with acute exacerbation [ALT > 10 × upper limit of normal (ULN), bilirubin 10 × ULN) plus Pegasys (180 μg/kg/week, when ALT was 5–10 × ULN) for 24 weeks. Thirteen HBeAg-negative patients (Group 2) had the same protocol for 48 weeks. In both groups, entecavir was then discontinued 14 days after the initiation of Pegasys.
To assess the safety and efficacy of sofosbuvir plus ledipasvir in patients with chronic HCV GT-1 that relapsed after sofosbuvir plus ribavirin therapy.
DESIGN:
Phase 2a, open-label study. (ClinicalTrials.gov: NCT01805882).
SETTING:
Single U.S site.
PATIENTS:
14 patients with HCV GT-1 that relapsed after treatment with sofosbuvir plus ribavirin for 24 weeks were re-treated with sofosbuvir plus ledipasvir for 12 weeks.
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Primary Outcome Measures:
•Percentage of subjects with sustained virologic response 12 weeks post-treatment [ Time Frame: 12 weeks after the last actual dose of active study drug ] [ Designated as safety issue:
Interim results will show that REP 9AC treatment rapidly leads to the detection of anti-HBsAg antibodies and the reduction and or clearance of serum HBsAg within the first 12 weeks of treatment in human patients. These findings are associated with substantial and sustained reductions in serum HBV titers which may be due to an improved immune response to the infection.
2) print out an article by Steve Tyring on the long term safety of acyclovir and see if your doctor will change his mind. I am attaching the entire abstract if it will fit, along with the reference, so you can go find it and print out the whole thing for him. Good luck.
J Infect Dis. 2002 Oct 15;186 Suppl 1:S40-6.
Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK, Baker D, Snowden W.
We aimed to evaluate the efficacy and safety of pegylated interferon (PEG-IFN) and ribavirin (RIB) in the treatment of post-OLT HCV recurrence.
Methods. Thirty-seven patients with recurrent HCV after OLT were screened and began treatment. Nineteen patients have completed therapy. PEG-IFN was started at a dose of 0.5 μg/kg per week and titrated toward a maximum dose of 1.5 μg/kg per week. RIB was started at a dose of 400 mg per day and titrated toward a maximum of 1000 mg per day, as tolerated.
the few lurking strands of virus re-emerge and multiply and the virus quickly becomes detectable again. Or the virus does not re-emerge. If your blood tests are clear for six months you are said to have achieved a Sustained Viral Response. The changes of the virus emerging after that point are very slight.
About 50% of patients with genotype 1 who treat for 48 weeks achieve SVR.
These drugs are highly toxic, cause mitochondrial toxicity, which further shuts down the immune system. Over time build of toxins causes cancers in other areas of the body.
So what is accomplished here? Just blocking viral DNA replication in blood does nothing in terms of cure. If they have very little effect on the surface antigen, that damages the liver cells even while on the medication.
None of these NUC drugs can be ever as effective as interferon.
To evaluate the efficacy and tolerability of an extended treatment protocol and to determine the predictors of sustained virological response (SVR) after liver transplantation (LT).
METHODS:
Between August 2005 and November 2008, patients with recurrent hepatitis C virus (HCV) after LT were selected for treatment if liver biopsy showed at least grade 2 inflammation and/or stage 2 fibrosis.
From HIVandHepatiis.com, a good site to bookmark:
http://www.hivandhepatitis.com/hep_c.html
With all the "Black Box" warnings on Procrit, this study is welcome news:
http://www.hivandhepatitis.com/hep_c/news/2008/072908_b.html
"Given the inherent differences in patient populations, practitioners should exercise caution when extrapolating the results of studies of other diseases to HCV infection," they added.
To evaluate safety and efficacy of pegylated interferon and ribavirin in chronic hepatitis C patients with heart disease.
METHODS:
Patients with overt heart disease (ischaemic heart disease, prior mechanical heart valve replacement, chronic arrhythmias and cardiomyopathy) and chronic hepatitis C were treated with standard pegylated interferon/ribavirin doses for standard duration.
Entry inhibitors for the treatment of acute and chronic hepatitis B and hepatitis D virus
infections.
Stephan Urban
Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg
For almost three decades after the discovery of Hepatitis B Virus (HBV) the early events of
infection (attachment, receptor binding and fusion) remained entirely unresolved.
The researchers evaluated 147 patients who initiated telaprevir-based triple therapy at Mount Sinai. The mean age of the cohort was 56 years, and 68% of the cohort was male, 19% was black, 46% did not respond to previous hepatitis C treatment, and 35% had advanced fibrosis or cirrhosis.
They calculated the cost of the therapy itself and the management of adverse events from Medicare, the Agency for Healthcare Research and Quality, and other sources.
Recommended
